EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck



Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck



Neoplasma 48(1): 66-71



Cysteine proteinases cathepsin (Cath) B and L and their endogenous inhibitors stefin (Stef) A and B concentrations were measured using a quantitative immunosorbent assay (ELISA; KRKA d.d., Novo mesto, Slovenia) in serum samples from 35 patients with primary and 7 patients with recurrent squamous cell carcinoma of the head and neck (SCCHN), obtained at diagnosis (Serum no.1) and after therapy (Serum no. 2), and compared to sera from 30 (Stef B, 90) healthy volunteers. A significantly higher Stef A (P = 0.005) and lower Stef B (P < 0.001) concentrations were measured in patients' Serum no.1 than in controls, and the levels of Caths B and L and Stef A were found to be significantly elevated in Serum no.1 as compared to Serum no. 2 (P = 0.045, P = 0.041 and P = 0.024, respectively). The time of Serum no.2 collection did not influence the concentration of either Caths or Stefs in these samples, and no correlation was observed with the established prognostic factors for any of the parameters studied. Patients with subsequently diagnosed recurrent disease had a significantly lower Cath L concentration than those without evidence of relapse during follow up (P = 0.05). The risk of disease recurrence and SCCHN-related death correlated significantly with low Cath L serum levels (P = 0.012, P = 0.006). The serum levels of Cath B, Stef A and Stef B did not influence significantly the probability of survival.

(PDF emailed within 1 workday: $29.90)

Accession: 010282426

Download citation: RISBibTeXText

PMID: 11327540



Related references

Stefin a and stefin B: markers for prognosis in operable squamous cell carcinoma of the head and neck. International Journal of Radiation Oncology, Biology, Physics 68(5): 1335-1341, 2007

The usefulness of new serum tumor markers in head and neck squamous cell carcinoma. Otolaryngology--Head and Neck Surgery 140(3): 375-380, 2009

Lipid-associated sialic acid, squamous cell carcinoma antigen, carcinoembryonic antigen, and lactic dehydrogenase levels as tumor markers in squamous cell carcinoma of the head and neck. Cancer (philadelphia). 70(10): 2499-2503, 1992

RCAS-1 serum and tumor levels in head and neck squamous cell carcinoma. European Surgical Research. Europaische Chirurgische Forschung. Recherches Chirurgicales Europeennes 44(3-4): 214-219, 2010

Serum levels of tumor necrosis factor in squamous cell carcinoma of the head and neck. American Journal of Otolaryngology 15(4): 281-285, 1994

Serum glycoproteins in head and neck squamous carcinoma: correlations with tumor extent, clinical tumor stage, and T-cell levels during chemotherapy. American Journal of Surgery 138(4): 489-500, 1979

Cathepsin D in tissue and serum of patients with squamous cell carcinoma of the head and neck. Cancer Letters. 130(1-2): 49-56,. 14, 1998

Investigation of urinary transforming growth factor alpha levels as tumor markers in patients with advanced squamous cell carcinoma of the head and neck. Head & Neck 12(5): 411-416, 1990

Expression of stefin A is of prognostic significance in squamous cell carcinoma of the head and neck. European Archives of Oto-Rhino-Laryngology 270(12): 3143-3151, 2014

A study of tumor markers cytokeratin 19 fragment and squamous cell carcinoma-related antigen in squamous cell carcinomas of the head and neck. Yonago Acta Medica 38(3): 205-220, 1995

Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients. Cancer Detection and Prevention 26(1): 42-49, 2002

A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head & Neck 27(9): 771-784, 2005

Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells. Oncology Reports 27(4): 1135-1141, 2012